Design Therapeutics (DSGN) Change in Accured Expenses (2020 - 2026)

Design Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 734.22% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at $2.3 million (up 126.92% YoY), while the FY2025 annual figure was $4.5 million, up 468.01% from the prior year.
• Change in Accured Expenses came in at -$2.5 million for Q1 2026 at Design Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q3 2022 to a low of -$2.8 million in Q4 2023.
• A 5-year average of $288823.5 and a median of $423000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 1726.92% in 2022 and tumbled 911.63% in 2023, its largest moves.
• Design Therapeutics' Change in Accured Expenses stood at $423000.0 in 2022, then plunged by 764.3% to -$2.8 million in 2023, then surged by 135.84% to $1.0 million in 2024, then jumped by 82.72% to $1.8 million in 2025, then tumbled by 236.47% to -$2.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$2.5 million, $1.8 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison